San Diego—After allogeneic hematopoietic cell transplantation (allo-HCT), ibrutinib provides durable control of chronic graft-versus-host disease (cGVHD) in patients who have failed corticosteroids, according to results of a Phase II trial.
The study reinforces positive results from a previously conducted Phase Ib study by the same group that led to a breakthrough designation by the FDA for ibrutinib (Imbruvica, Pharmacyclics) for this indication.
Responses were seen across multiple